

Wednesday 19 June

14:00	<b>Registration desk open</b> Refreshments on Basement Level	Ground Level
15:00-16:00	<b>BSGCT Annual General Meeting</b>	Lecture Theatre 3
16:00-18:15	<b>Welcome &amp; Symposium 1: Hot topics</b> Chairs: Peter Andrews, <i>University of Sheffield</i> ; Sophia kleine Holthaus, <i>UCL Institute of Ophthalmology</i>	LT3
16:00-16:10	Welcome	
16:10-16:50	<b>INV01</b> <b>KEYNOTE: Development of cell transplantation for Parkinson's disease</b> Roger Barker, <i>University of Cambridge</i>	
16:50-17:15	<b>INV02</b> <b>From bench to bedside: Intrathecal gene therapy for Batten disease</b> Kathrin Meyer, <i>Nationwide Children's Hospital, Ohio</i>	
17:15-17:40	<b>INV03</b> <b>Efficient <i>in vivo</i> editing of patient-derived primary human hepatocytes</b> Samantha Ginn, <i>AGCTS/CMRI, Sydney</i>	
17:40-18:05	<b>INV04</b> <b>Gene therapy of mtDNA disease</b> Michal Minczuk, <i>University of Cambridge</i>	
18:05-18:15	<b>1 minute rapid poster presentations</b>	LT3
19:00-20:45	<b>BSGCT Welcome Networking Reception</b> Sponsored by Synpromics and Oxford Biomedica	Sheffield Winter Gardens Surrey Street, S1 2LH

## Programme

Thursday 20 June

08:15	Registration desk open	Ground Level
08:45-10:30	<b>Symposium 2: Monogenic/rare diseases</b> Chairs: Laura Ferraiulo, <i>University of Sheffield</i> ; Nora Clarke, <i>Imperial College London</i>	LT3
08:45-09:10	<b>INV05</b> <b>Gene therapeutics for motor neuron diseases and frontotemporal dementia</b> Mimoun Azzouz, <i>University of Sheffield</i>	
09:10-09:35	<b>INV06</b> <b>Tay-Sachs and Sandhoff diseases - a rare therapeutic opportunity in the brain</b> Timothy Cox, <i>University of Cambridge</i>	
09:35-10:00	<b>INV07</b> <b>Gene therapy for pulmonary disorders</b> Uta Griesenbach, <i>Imperial College London</i>	
10:00-10:15	<b>OR01</b> <b>Onasemnogene abeparvovec gene-replacement therapy for spinal muscular atrophy: From bench to bedside</b> Imran Kausar, <i>AveXis Inc, Bannockburn, IL</i>	
10:15-10:30	<b>OR02</b> <b>AAV9 gene therapy rescue of an eEF1A2 knockout mouse model</b> Rajvinder Karda, <i>University College London</i>	
10:30-11:00	Refreshments	Basement Level
11:00-12:35	<b>Symposium 3 (parallel): Ocular disorders</b> Chairs: Ivana Barbaric, <i>University of Sheffield</i> ; Emily Bates, <i>Cardiff University</i>	LT3
11:00-11:25	<b>INV08</b> <b>A review of the current state of RPE transplantation for treating AMD</b> Pete Coffey, <i>University College London</i>	

## Thursday 20 June

- 
- 11:25-11:50 **INV09**  
**Gene therapy for Leber hereditary optic neuropathy**  
Patrick Yu-Wai-Man, *University of Cambridge*
- 
- 11:50-12:05 **OR03**  
**The therapeutic potential of AAV-ophNdi1 for the treatment of Leber hereditary optic neuropathy (LHON)**  
Naomi Chadderton, *Trinity College, Dublin*
- 
- 12:05-12:20 **OR04**  
**Characterisation of a retinal ganglion cell promoter**  
Sophia Millington-Ward, *Trinity College, Dublin*
- 
- 12:20-12:35 **OR05**  
**Effect of human vitreous humour components and neutralising antibodies on transduction activity of recombinant AAV2, AAV5, AAV6 and AAV8**  
Slawomir Andrzejewski, *LVF Ophthalmology Research Centre, Brisbane*
- 
- 11:00-12:35** **Symposium 4 (parallel): Viral and non-viral vector development** LT4  
Chairs: Uta Griesenbach, *Imperial College London*;  
João Cruzeiro, *University of Sheffield*
- 
- 11:00-11:25 **INV10**  
**Bacteriophage: From applications in infectious diseases to targeted systemic gene therapy of human cancer**  
Amin Hajitou, *Imperial College London*
- 
- 11:25-11:50 **INV11**  
**Therapeutic DNA vaccination: RALA peptide-mediated gene delivery via dissolving microneedles**  
Helen McCarthy, *Queen's University Belfast*
- 
- 11:50-12:05 **OR06**  
**Adeno-associated viral vectored delivery of a monoclonal antibody gene against blood-stage malaria**  
Martino Bardell, *University of Oxford*

## Programme

### Thursday 20 June

---

12:05-12:20	<b>OR07</b> <b>Efficient and scalable production systems for viral vector manufacture</b> Qian Liu, <i>Oxford Genetics Ltd</i>	
12:20-12:35	<b>OR08</b> <b>Virus-free production of CAR-T cells for the treatment of solid tumors</b> Pavel Simara, <i>International Clinical Research Center, St. Anne's University Hospital Brno</i>	
<b>12:35-14:00</b>	<b>Lunch &amp; Posters</b>	Basement & Ground Level
<b>13:00-13:30</b>	<b>Stemcell Technologies Symposium</b> <b>Ensuring high-quality hPSC cultures through stabilized maintenance conditions</b> Brian Duff, <i>Stemcell Technologies</i>	LT3
		
<b>14:00-15:50</b>	<b>Symposium 5 (parallel): CNS and autoimmune disorders</b> Chairs: Basil Sharrack, <i>University of Sheffield</i> ; Jack Hickmott, <i>Imperial College London</i>	LT3
14:00-14:25	<b>INV12</b> <b>Autologous haematopoietic stem cell transplantation for severe treatment resistant autoimmune diseases</b> Basil Sharrack and John Snowden, <i>University of Sheffield</i>	
14:25-14:50	<b>INV13</b> <b>Haematopoietic stem cell gene therapy and inflammation in CNS lysosomal diseases</b> Brian Bigger, <i>University of Manchester</i>	
14:50-15:05	<b>OR09</b> <b>Long-term neurological correction is sustained in mucopolysaccharidosis IIIB mice following haematopoietic stem cell gene therapy</b> Stuart Ellison, <i>University of Manchester</i>	
15:05-15:20	<b>OR10</b> <b>Development of novel synthetic promoters for CNS gene therapy</b> Maha Tijani, <i>University College London</i>	

Thursday 20 June

15:20-15:35	<b>OR11</b> <b>A stem cell model of spinal muscular atrophy (SMA): Assessing combinatorial drug therapies</b> Vinay Kumar Godena, <i>University of Sheffield</i>	
15:35-15:50	<b>OR12</b> <b>AAV Gene therapy approach for the treatment of Dravet syndrome</b> Juan Antinao Diaz, <i>University College London</i>	
<b>14:00-15:50</b>	<b>Symposium 6 (parallel): Haematological disorders and immunology</b> Chairs: Kyriacos Mitrophanous, <i>Oxford Biomedica</i> ; Shaun Wood, <i>University of Manchester</i>	<b>LT4</b>
14:00-14:25	<b>INV14</b> <b>Harnessing the potential of V<math>\delta</math>1 gamma delta T cells</b> Natalie Mount, <i>GammaDelta Therapeutics, London</i>	
14:25-14:50	<b>INV15</b> <b>Gene therapy for haemophilia: Progress and problems</b> Edward Tuddenham, <i>University College London</i>	
14:50-15:05	<b>OR13</b> <b>New strategy of cancer vaccination by a hybrid bacteriophage vector and a malaria vaccine</b> Sajee Waramit, <i>Imperial College London</i>	
15:05-15:20	<b>OR14</b> <b>Defining the immunological properties of hESC-derived otic neural progenitors in the context of the gerbil auditory neuropathy model</b> Leila Abbas, <i>University of Sheffield</i>	
15:20-15:35	<b>OR15</b> <b>Use of heterologous vesiculovirus G proteins circumvents the humoral anti-envelope immunity in lentivector based <i>in vivo</i> gene delivery</b> Yasuhiro Takeuchi, <i>University College London</i>	
15:35-15:50	<b>OR16</b> <b>Gene therapy for thrombotic thrombocytopenic purpura</b> Robyn Bell, <i>Imperial College London</i>	

## Programme

Thursday 20 June

---

<b>15:50-16:30</b>	<b>Refreshments</b>	<b>Basement Level</b>
<b>16:30-17:20</b>	<b>Symposium 7: Funding and Regulatory</b> Chairs: Rafael Yáñez-Muñoz, <i>Royal Holloway, University of London</i> ; Stuart Ellison, <i>University of Manchester</i>	<b>LT3</b>
16:30-16:55	<b>INV16</b> <b>Advanced therapies VC funding outlook 2019</b> Dmitry Kuzmin, <i>4BIO Capital, London</i>	
16.55-17:20	<b>INV17</b> <b>Advance therapy treatment centres</b> Jackie Barry, <i>Cell and Gene Therapy Catapult, London</i>	
<b>17:20-18:00</b>	<b>Panel session – challenges in clinical translation</b>	
<b>18:00-19:00</b>	<b>BSGCT Exhibition, Drinks, Posters</b>	<b>Ground Level and Basement</b>
<b>19:30</b>	<b>Conference Networking Dinner</b> Sponsored by Stemcell Technologies <b>After Dinner Speaker:</b> Peter Goodfellow, FRS	<b>Cutlers' Hall Church Street, S1 1HG</b>



Friday 21 June

<b>08:15</b>	<b>Registration desk open</b>	<b>Ground Level</b>
<b>08:15-09:00</b>	<b>Refreshments including breakfast rolls</b>	<b>Basement Level</b>
<b>09:00-10:20</b>	<b>Symposium 8: Cancer</b> Chairs: Amin Hajitou, <i>Imperial College London</i> ; Jason Halliwell, <i>University of Sheffield</i>	<b>LT3</b>
09:00-09:25	<b>INV18</b> <b>The promise of iNKT cells as a versatile platform for chimaeric antigen receptor-based immunotherapy of blood cancers</b> Anastasios Karadimitris, <i>Imperial College London</i>	
09:25-09:50	<b>INV19</b> <b>Improved replication and selectivity of oncolytic Ad<math>\Delta\Delta</math> and Ad-3<math>\Delta</math>-A20T promotes targeting to distant lesions in preclinical pancreatic cancer models</b> Gunnel Halldén, <i>Queen Mary University of London</i>	
09:50-10:05	<b>OR17</b> <b>Evaluation of the <math>\alpha\upsilon\beta6</math> selective precision virotherapy Ad5NULL-A20 as an effective oncolytic virotherapy for pancreatic and triple negative breast cancers</b> James Davies, <i>Cardiff University</i>	
10:05 - 10:20	<b>OR18</b> <b>Targeting the tumour vasculature with CAR-T cells for treatment of solid tumours</b> Juan Miguel Sanchez-Nieto, <i>Cell and Gene Therapy Catapult, London</i>	
<b>10:20-11:10</b>	<b>Refreshments</b>	<b>Basement Level</b>
<b>11:10-12:30</b>	<b>Symposium 9: Pulmonary and cardiac disease</b> Chairs: Mustafa Munye, <i>Cell and Gene Therapy Catapult, London</i> ; Dylan Stavish, <i>University of Sheffield</i>	<b>LT3</b>
11:10-11:35	<b>INV20</b> <b>Tissue engineering for cardiovascular repair</b> Richard Jabbour, <i>Imperial College London</i>	
11:35-12:00	<b>INV21</b> <b>TACTICAL: A phase I/II trial to assess the safety and efficacy of MSCTRAIL in metastatic lung adenocarcinoma</b> Beth Sage, <i>University College London</i>	

## Programme

### Friday 21 June

---

12:00-12:15	<b>OR19</b> <b>Immune suppression for xeno-cell transplantation strategies in the porcine animal model</b> Evelyne Demkes, <i>University Medical Center Utrecht</i>	
12:15-12:30	<b>OR20</b> <b>Allele specific repair of splicing mutations in cystic fibrosis through AsCas12a genome editing</b> Gianluca Petris, <i>University of Trento</i>	
<b>12:30-13:30</b>	<b>Lunch</b>	Basement & Ground Level
<b>13:00-13:30</b>	<b>Synpromics Ltd Symposium</b> <b>Mastering gene control to enable the next generation of gene medicines</b> Michael Roberts, <i>Synpromics Ltd</i> 	LT3
<b>13:30-15:00</b>	<b>BSGCT Special Lecture and Fairbairn Award presentations</b> Chairs: Mimoun Azzouz, <i>University of Sheffield</i> ; Evangelia Karyka, <i>University of Sheffield</i> Sponsored by Cancer Research UK Manchester Institute 	LT3
13:30-13:45	<b>Fairbairn 1</b> <b>OR21</b> <b>Bacteriophage-mediated systemic gene therapy of diffuse intrinsic pontine glioma through the blood-brain barrier</b> Wenqing Yan, <i>Imperial College London</i>	
13:45-14:00	<b>Fairbairn 2</b> <b>OR22</b> <b>Adipose derived stem cells for cell therapy of Motor Neuron Disease (MND)</b> Yuri Ciervo, <i>University of Sheffield</i>	



## Friday 21 June

- 
- 14:00-14:15 **Fairbairn 3**  
**OR23**  
**Adenovirus serotype 26 uses sialic acid bearing glycans as its primary means of infection**  
*Alexander Baker, Cardiff University*
- 
- 14:15-14:30 **Fairbairn 4**  
**OR24**  
**Transient reprogramming of cardiomyocytes to a proliferative de-differentiated state**  
*Thomas Kisby, University of Manchester*
- 
- 14:30-15:05 **INV22**  
**KEYNOTE: Cell therapy for leukaemia: Development and current status of Kymriah**  
*Stephan Grupp, Children's Hospital of Philadelphia*
- 
- 15:05** **Concluding remarks and awards ceremony**